RSS-Feed abonnieren
PDF herunterladen
DOI: 10.1055/s-0044-1793833
Intrahepatic Cholangiocarcinoma Presenting as an Incidentaloma on F-18 PYL PSMA PET/CT
Abstract
Cholangiocarcinoma is an aggressive malignancy arising from the biliary tract epithelium with rising incidence and mortality. Imaging commonly used for diagnostic workup includes computed tomography (CT) scan and magnetic resonance imaging (MRI). Fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) scans can be used for investigating equivocal findings on radiographic imaging. Prostate-specific membrane antigen (PSMA) is known to be highly expressed in prostate adenocarcinoma, allowing it to be leveraged as a target for both imaging and radioligand therapy in prostate cancer. However, PSMA is also commonly expressed in other malignancies such as breast cancer, thyroid carcinomas, and head and neck malignancies, which increase the chances of their incidental diagnosis on PSMA PET scans. Biliary tract cancers, including cholangiocarcinoma, are not commonly expected to be incidentally diagnosed on PSMA PET imaging. Here, we describe the case of a patient with known prostate adenocarcinoma who was later incidentally diagnosed with advanced intrahepatic cholangiocarcinoma on PSMA PET/computed tomography (CT). This case highlights the unexpected finding of cholangiocarcinoma on PSMA PET/CT and suggests further investigation into the role of PSMA PET in diagnosing ambiguous cases of cholangiocarcinoma and its potential theranostic applications.
Keywords
cholangiocarcinoma - incidentaloma - intrahepatic cholangiocarcinoma - PSMA PET/CT - theranosticsPublikationsverlauf
Artikel online veröffentlicht:
13. November 2024
© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Gad MM, Saad AM, Faisaluddin M. et al. Epidemiology of cholangiocarcinoma; United States incidence and mortality trends. Clin Res Hepatol Gastroenterol 2020; 44 (06) 885-893
- 2 Bertagna F, Albano D, Giovanella L. et al. 68Ga-PSMA PET thyroid incidentalomas. Hormones (Athens) 2019; 18 (02) 145-149
- 3 Zhou W, Halder S, Herwald S. et al. Frequent amplification and overexpression of PSMA in basallike breast cancer from analysis of The Cancer Genome Atlas. J Nucl Med 2024; 65 (07) 1004-1006
- 4 Lawhn-Heath C, Flavell RR, Glastonbury C, Hope TA, Behr SC. Incidental detection of head and neck squamous cell carcinoma on 68Ga-PSMA-11 PET/CT. Clin Nucl Med 2017; 42 (04) e218-e220
- 5 Chen LX, Zou SJ, Li D. et al. Prostate-specific membrane antigen expression in hepatocellular carcinoma, cholangiocarcinoma, and liver cirrhosis. World J Gastroenterol 2020; 26 (48) 7664-7678
- 6 Kang C, Jiang JY, Lee ME, Shen L, Mansberg R. Incidental intrahepatic hepatocellular cholangiocarcinoma detected on 68Ga-PSMA PET/CT. Clin Nucl Med 2022; 47 (03) e291-e293
- 7 Veenstra MMK, Vegt E, Segbers M. et al. Intra-arterial PSMA injection using hepatic arterial infusion pump in intrahepatic cholangiocarcinoma: a proof-of-concept study. Eur Radiol Exp 2024; 8 (01) 90
- 8 Sun Y, Wang H, Yang Y, You Z, Zhao J. Intrahepatic cholangiocarcinoma detected on 18F-PSMA-1007 PET/MR imaging in a prostate cancer patient: a case report and literature review. Front Oncol 2024; 14: 1408453
- 9 Chen W, Lee Z, Awadallah A, Zhou L, Xin W. Peritumoral/vascular expression of PSMA as a diagnostic marker in hepatic lesions. Diagn Pathol 2020; 15 (01) 92